Compare AMR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMR | SNDX |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2017 | 2014 |
| Metric | AMR | SNDX |
|---|---|---|
| Price | $165.56 | $19.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $181.50 | $38.69 |
| AVG Volume (30 Days) | 273.8K | ★ 1.4M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,129,481,000.00 | $172,352,000.00 |
| Revenue This Year | $15.05 | $107.19 |
| Revenue Next Year | $14.78 | $41.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $133.64 | $13.00 |
| 52 Week High | $253.82 | $25.59 |
| Indicator | AMR | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.75 | 42.55 |
| Support Level | $152.33 | $19.28 |
| Resistance Level | $213.65 | $22.40 |
| Average True Range (ATR) | 7.56 | 1.01 |
| MACD | 3.33 | -0.06 |
| Stochastic Oscillator | 98.19 | 65.07 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.